Alto Neuroscience, Inc. (NYSE:ANRO) Stock Has Consensus Price Target of $37.88 According to Brokerages

Alto Neuroscience, Inc. (NYSE:ANRO) has received a consensus rating of “Moderate Buy” from the eleven brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $37.88.

Several research analysts have weighed in on ANRO shares. HC Wainwright upped their price objective on shares of Alto Neuroscience from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, October 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a report on Tuesday, October 27th. Zacks Research raised shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. Wall Street Zen downgraded shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, September 12th. Finally, BTIG Research upped their target price on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, August 13th.

Alto Neuroscience Price Performance

Shares of NYSE:ANRO opened at $28.75 on Wednesday. The company has a quick ratio of 14.85, a current ratio of 14.85 and a debt-to-equity ratio of 0.07. Alto Neuroscience has a twelve month low of $10.80 and a twelve month high of $37.48. The stock’s 50 day moving average is $26.71 and its 200-day moving average is $24.43. The firm has a market capitalization of $1.13 billion, a price-to-earnings ratio of -11.88 and a beta of 1.42.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.13. Sell-side analysts forecast that Alto Neuroscience will post -2.69 EPS for the current fiscal year.

Insider Transactions at Alto Neuroscience

In other Alto Neuroscience news, CFO Nicholas Smith sold 110,830 shares of the business’s stock in a transaction that occurred on Tuesday, September 29th. The stock was sold at an average price of $26.58, for a total transaction of $2,945,861.40. Following the completion of the sale, the chief financial officer directly owned 24,060 shares of the company’s stock, valued at approximately $639,514.80. The trade was a 82.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 11.25% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Commodore Capital LP grew its holdings in Alto Neuroscience by 49.4% during the first quarter. Commodore Capital LP now owns 2,723,196 shares of the company’s stock worth $61,217,000 after buying an additional 900,000 shares in the last quarter. Perceptive Advisors LLC raised its position in Alto Neuroscience by 12.6% in the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock valued at $45,182,000 after buying an additional 225,500 shares during the last quarter. Spruce Street Capital LP raised its position in Alto Neuroscience by 494.7% in the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock valued at $29,116,000 after buying an additional 1,102,366 shares during the last quarter. Affinity Asset Advisors LLC bought a new position in Alto Neuroscience during the 1st quarter valued at $11,240,000. Finally, Jennison Associates LLC bought a new position in Alto Neuroscience during the 1st quarter valued at $8,687,000.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.